HCA Healthcare (HCA) Stock Forecast & Price Target

$334.38 +3.38 (+1.02%)

Closing price 03:59 PM Eastern

Extended Trading

$334.92 +0.55 (+0.16%)

As of 06:13 PM Eastern

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
1

Hold
6

Buy
12

Based on 19 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for HCA.

Consensus Price Target

$381.67
14.14% Upside

According to the 19 analysts' twelve-month price targets for HCA Healthcare, the average price target is $381.67. The highest price target for HCA is $440.00, while the lowest price target for HCA is $320.00. The average price target represents a forecasted upside of 14.14% from the current price of $334.38.

Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

HCA Analyst Ratings Over Time

Type	Current Forecast 4/17/24 to 4/17/25	1 Month Ago 3/18/24 to 3/18/25	3 Months Ago 1/18/24 to 1/17/25	1 Year Ago 4/18/23 to 4/17/24
Strong Buy	1 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)
Hold	6 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$381.67	$385.67	$385.27	$314.05
Forecasted Upside	14.14% Upside	16.88% Upside	24.04% Upside	0.97% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.63	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.14% Upside	21,674.01% Upside	26.48% Upside
News Sentiment Rating	Positive News See Recent HCA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/15/2025	Baird R W 0 of 5 stars	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	Robert W. Baird 2 of 5 stars	Michael Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$396.00 ➝ $336.00	-1.39%
4/9/2025	Guggenheim 2 of 5 stars	Jason Cassorla Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
1/27/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kevin Fischbeck Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$380.00 ➝ $370.00	+12.36%
1/27/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$405.00 ➝ $384.00	+16.61%
1/27/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$405.00 ➝ $405.00	+29.60%
1/27/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$392.00 ➝ $366.00	+17.12%
1/7/2025	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Gillmor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$420.00 ➝ $370.00	+20.54%
1/6/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$430.00 ➝ $390.00	+31.45%
12/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$406.00 ➝ $355.00	+15.41%
Get the Latest News and Ratings for HCA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for HCA Healthcare and its competitors with MarketBeat's FREE daily newsletter.
12/17/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$380.00	+22.74%
11/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$400.00 ➝ $320.00	-1.52%
11/22/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Ransom Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/28/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$450.00 ➝ $440.00	+22.05%
10/28/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$390.00 ➝ $400.00	+10.22%
8/29/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Lake Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$405.00 ➝ $438.00	+18.74%
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$367.00 ➝ $396.00	+16.32%
6/28/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$359.00 ➝ $375.00	+14.85%
1/4/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$277.00 ➝ $301.00	+9.85%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$271.00	+5.23%
11/10/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$280.00	+20.26%
10/25/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$325.00 ➝ $275.00	+21.19%
10/25/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$324.00 ➝ $279.00	+22.87%
7/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$311.00 ➝ $316.00	+14.31%
6/28/2023	1-800-FLOWERS.COM Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/10/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $310.00	+13.12%
4/24/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $350.00	+23.24%
4/24/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $320.00	+13.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:58 PM ET.

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, April 14, 2025. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

HCA Healthcare, Inc. reported a strong earnings per share (EPS) of $6.22 for the latest quarter, surpassing the consensus estimate of $6.03 by $0.19, indicating robust financial performance.
The company has a high return on equity (ROE) of 586.47%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
HCA Healthcare, Inc. recently increased its quarterly dividend to $0.72 per share, up from $0.66, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend of $2.88, providing a yield of 0.86%.
The stock is currently trading at $333.07, which is within a reasonable range compared to its 1-year high of $417.14, potentially offering a buying opportunity for investors looking for growth.
Analysts have a consensus rating of "Moderate Buy" for HCA Healthcare, Inc., with a target price averaging $385.67, indicating potential upside for investors.

HCA Healthcare
Bear Case

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

The stock has experienced volatility, with a beta of 1.48, indicating that it is more volatile than the market, which could pose risks for conservative investors.
HCA Healthcare, Inc. has a relatively high debt-to-equity ratio of 69.07, suggesting that the company relies significantly on debt financing, which could impact financial stability in adverse conditions.
Recent price target reductions by analysts, such as Barclays lowering their target from $392.00 to $366.00, may indicate concerns about future growth prospects.
Despite the recent dividend increase, the dividend payout ratio is 13.11%, which, while sustainable, may limit future dividend growth potential if earnings do not increase significantly.
Market conditions and regulatory changes in the healthcare sector could adversely affect HCA Healthcare, Inc.'s operations and profitability, introducing uncertainty for investors.

HCA Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $381.67, with a high forecast of $440.00 and a low forecast of $320.00.
: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last year. There is currently 1 sell rating, 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HCA shares.
: According to analysts, HCA Healthcare's stock has a predicted upside of 14.14% based on their 12-month stock forecasts.
: Over the previous 90 days, HCA Healthcare's stock had 1 downgrade by analysts.
: HCA Healthcare has been rated by research analysts at Baird R W, Bank of America, Barclays, Cantor Fitzgerald, Guggenheim, Robert W. Baird, and Royal Bank of Canada in the past 90 days.
: Analysts like HCA Healthcare less than other "medical" companies. The consensus rating score for HCA Healthcare is 2.63 while the average consensus rating score for "medical" companies is 2.81. Learn more on how HCA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:HCA) was last updated on 4/17/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCA Healthcare (HCA) Stock Forecast & Price Target